Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...

Nephrotic Syndrome III : Nursing Management

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Defining interstitial lung disease related to idiopathic inflammatory myopathies: a systematic review protocol of the Myositis Clinical Trial Consortium (MCTC).

Systematic reviews·2026

Same author

Are we ready to predict progressive disease in juvenile systemic sclerosis?

Journal of scleroderma and related disorders·2026

Same author

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.

Journal of scleroderma and related disorders·2026

Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026

Same author

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Expert review of clinical immunology·2026

Same author

Calcinosis Cutis and Delayed-Onset Myositis in a Case of Suspected Localized Scleroderma: A Diagnostic and Therapeutic Challenge.

Pediatric dermatology·2026

Same journal

Flow cytometry-based basophil and mast cell activation tests for IgE-mediated food and drug allergy: have we crossed the Rubicon?

Expert review of clinical immunology·2026

Same journal

An update on the pharmacotherapy of ANCA-associated vasculitis.

Expert review of clinical immunology·2026

Same journal

Targeting the cytokine storm: new therapies in the treatment of pediatric hemophagocytic lymphohistiocytosis.

Expert review of clinical immunology·2026

Same journal

Why is the antigen uptake receptor DEC205 (CD205) of interest?

Expert review of clinical immunology·2026

Same journal

Infectious disease screening in rheumatological patients: a narrative review on methods, risk stratification and clinical management.

Expert review of clinical immunology·2026

Same journal

An update on our understanding of host defense mechanisms at the ocular surface; innate immune dysregulation at the ocular surface: lessons from Stevens-Johnson syndrome and related inflammatory disorders.

Expert review of clinical immunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 23, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Systemic therapy in juvenile localized scleroderma.

Ivan Foeldvari¹, Edoardo Marrani²

¹Hamburger Zentrum Für Kinder- Und Jugendrheumatologie, Hamburg, Germany.

Expert Review of Clinical Immunology

|July 18, 2023

Summary

This summary is machine-generated.

Early treatment of juvenile localized scleroderma (JLS) is crucial to prevent long-term disability. This review outlines disease assessment and a treat-to-target systemic therapy plan, including methotrexate as a first-line option.

Keywords:

Autologous fat transplantation JAK inhibitors damage disease modifying agents inactive disease localized scleroderma morphea outcome remission

More Related Videos

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Experiment Videos

Last Updated: Jul 23, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

Pediatric rheumatology
Dermatology
Autoimmune connective tissue diseases

Background:

Juvenile localized scleroderma (JLS) is a rare childhood condition causing significant morbidity if untreated.
Prompt intervention during the inflammatory phase is essential to prevent permanent damage and functional disability.

Purpose of the Study:

To review methods for assessing disease activity and damage in JLS.
To propose a systemic treatment escalation strategy based on a treat-to-target approach.
To define criteria for inactive disease and medication discontinuation.

Main Methods:

Discussion of baseline disease activity assessment for treatment monitoring.
Emphasis on evaluating extra-cutaneous involvement.
Proposal of a tiered systemic treatment approach, prioritizing methotrexate as first-line therapy.

Main Results:

Systemic treatment is recommended for most JLS patients.
Methotrexate is the preferred first-line disease-modifying anti-rheumatic drug (DMARD).
A treatment escalation plan is necessary for cases of methotrexate intolerance or non-response.

Conclusions:

Timely assessment and intervention in JLS are critical.
A structured, treat-to-target approach with potential escalation is vital for managing JLS.
Further research into prognostic markers is needed to guide treatment decisions.